Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invitae Corp (NY: NVTA )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Feb 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invitae Corp

< Previous 1 2 3 4 5 6 7 8 9 Next >
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
Understanding Invitae's Unusual Options Activity
On Tuesday, shares of Invitae (NYSE:NVTA) saw unusual optio... 
Via Benzinga
Invitae's Earnings: A Preview
Invitae (NYSE:NVTA) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
3 Cathie Wood Stocks to Watch This Earnings Season
All eyes will be watching these ARK Invest holdings to see if they're working out as hoped. 
Via The Motley Fool
Cathie Wood Goes Bargain Shopping: 3 Sinking Stocks She Keeps Buying
The CEO of ARK Invest is averaging down on these compelling life-science stocks. 
Via The Motley Fool
Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought
All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Cardiff Oncology (NASDAQ: 
Via Benzinga
Invitae Strengthens Health Data Platform With Ciitizen Acquisition
Invitae Corp (NYSE: NVTA) has agreed to acquire consumer health technology company Ciitizen for $325 million in a bid to make it easier for patients to collect... 
Via Benzinga
Return on Capital Employed Overview: Invitae
After pulling data from Benzinga Pro it seems like during Q2, Invitae (NYSE:NVTA) earned $128.61 million, a 214.46% increase from the preceding quarter. Invitae also posted a... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap to set a new 52-week low was Koninklijke Philips (NYSE... 
Via Benzinga
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
20 Stocks Moving in Monday's Pre-Market Session
Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT) shares rose 55.8% to $2.82 in pre-market trading after dropping over 10% on Friday. The company recently reported a wider loss... 
Via Benzinga
Why Did Invitae Stock Fall 17% in July?
This genetic testing innovator slumped along with other genomics stocks last month. 
Via The Motley Fool
Why Invitae Stock Is Climbing Today
Accelerating growth is giving investors more confidence in the genetic testing company's long-term prospects. 
Via The Motley Fool
88 Biggest Movers From Yesterday
Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021
Upgrades For Meritage Homes Corp (NYSE: 
Via Benzinga
Invitae Stock Jumps As Higher Test Volume More Than Doubles Q2 Topline, Raises FY21 Sales Outlook
Invitae Corporation (NYSE: NVTA), after the close of the market on Tuesday, reported its second-quarter revenues of $116.3 million, +152% Y/Y, exceeding the consensus... 
Via Benzinga
Invitae (NVTA) Q2 2021 Earnings Call Transcript
NVTA earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
30 Stocks Moving in Wednesday's Pre-Market Session
Gainers Alterity Therapeutics Limited (NASDAQ: ATHE) shares rose 34.8% to $1.84 in pre-market trading after gaining around 3% on Tuesday. Wheeler Real Estate Investment Trust,... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Cerus (NASDAQ:CERS) shares incre... 
Via Benzinga
14 Stocks Moving In Tuesday's After-Hours Session
RingCentral (NYSE: RNG) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results and issued Q3 and FY21 EPS and sales guidance above... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
Pacific Biosciences To Buy DNA Sequencing Firm For Up To $800M, Announces $300M Capital Raise For Deal Funding
Pacific Biosciences of California Inc (NASDAQ: PACB) has agreed to acquire Omniome, a San Diego-based company developing a short-read sequencing platform. Under... 
Via Benzinga
Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news. 
Via The Motley Fool
3 Things About Invitae That Smart Investors Should Know
Could Invitae become the first $1 trillion market cap healthcare company? 
Via The Motley Fool
Analyzing Invitae's Unusual Options Activity
On Thursday, shares of Invitae (NYSE:NVTA) saw unusual options activity. After the option alert, the stock price moved up to $31.08. Sentiment: BULLISH Option Type: SWEEP Trade... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.